5,739,064 Shares in Recursion Pharmaceuticals, Inc. $RXRX Purchased by Norges Bank

Norges Bank bought a new position in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund bought 5,739,064 shares of the company’s stock, valued at approximately $23,473,000.

Several other hedge funds and other institutional investors have also modified their holdings of RXRX. International Assets Investment Management LLC bought a new stake in shares of Recursion Pharmaceuticals during the 4th quarter worth about $31,000. Sequoia Financial Advisors LLC acquired a new stake in Recursion Pharmaceuticals in the 4th quarter worth about $41,000. Allworth Financial LP raised its stake in Recursion Pharmaceuticals by 85.6% in the 3rd quarter. Allworth Financial LP now owns 9,548 shares of the company’s stock worth $47,000 after purchasing an additional 4,403 shares in the last quarter. IFP Advisors Inc raised its stake in Recursion Pharmaceuticals by 81.5% in the 3rd quarter. IFP Advisors Inc now owns 10,355 shares of the company’s stock worth $51,000 after purchasing an additional 4,650 shares in the last quarter. Finally, Ethos Financial Group LLC acquired a new stake in Recursion Pharmaceuticals in the 4th quarter worth about $53,000. Institutional investors own 89.06% of the company’s stock.

Recursion Pharmaceuticals Trading Down 3.0%

Shares of Recursion Pharmaceuticals stock opened at $3.22 on Wednesday. Recursion Pharmaceuticals, Inc. has a 1 year low of $2.77 and a 1 year high of $7.18. The company has a current ratio of 5.47, a quick ratio of 5.47 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $1.71 billion, a PE ratio of -2.68 and a beta of 1.04. The firm’s 50 day moving average is $3.31 and its 200 day moving average is $3.80.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its earnings results on Wednesday, May 6th. The company reported ($0.22) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.08. Recursion Pharmaceuticals had a negative net margin of 842.95% and a negative return on equity of 54.33%. The firm had revenue of $6.47 million for the quarter, compared to analyst estimates of $15.78 million. During the same period in the previous year, the firm posted ($0.50) EPS. The company’s revenue for the quarter was down 56.8% compared to the same quarter last year. Equities research analysts forecast that Recursion Pharmaceuticals, Inc. will post -0.99 earnings per share for the current fiscal year.

Insider Activity at Recursion Pharmaceuticals

In related news, Director Blake Borgeson sold 30,000 shares of the business’s stock in a transaction on Tuesday, June 2nd. The shares were sold at an average price of $3.68, for a total transaction of $110,400.00. Following the transaction, the director owned 6,169,863 shares in the company, valued at $22,705,095.84. The trade was a 0.48% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Najat Khan sold 23,588 shares of the business’s stock in a transaction on Friday, June 5th. The shares were sold at an average price of $3.58, for a total transaction of $84,445.04. Following the transaction, the chief executive officer owned 2,175,796 shares in the company, valued at $7,789,349.68. The trade was a 1.07% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 125,930 shares of company stock worth $435,942 in the last quarter. Company insiders own 8.43% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have weighed in on RXRX. Bank of America dropped their price objective on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a “neutral” rating for the company in a research note on Wednesday, February 25th. Morgan Stanley lifted their price objective on shares of Recursion Pharmaceuticals from $5.00 to $5.50 and gave the stock an “equal weight” rating in a research note on Thursday, May 14th. Weiss Ratings restated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research report on Tuesday, April 21st. JPMorgan Chase & Co. dropped their target price on shares of Recursion Pharmaceuticals from $11.00 to $10.00 and set an “overweight” rating for the company in a research report on Thursday, April 30th. Finally, Wall Street Zen cut shares of Recursion Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, March 28th. Two equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $8.10.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.